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Background. The purpose of this study was to evaluate the combination of an enamel matrix derivative (EMD) and an
osteoconductive bone ceramic (BC) in improving bone regeneration. Materials and Methods. Four cylindrical cavities (6 ×6mm)
were prepared bilaterally in the mandible in three dogs. The defects were randomly assigned to four diﬀerent treatments—ﬁlled
withEMD/BCandcoveredwithanonresorbablemembrane,ﬁlledwithEMD/BCwithoutmembrane,membranecoverageonly,or
control (left untreated)—and healed for 2, 4, or 6 weeks. Harvested specimens were prepared for histologic, histomorphometric,
and immunohistochemical analyses. Results. Sites treated with EMD/BC with or without membrane showed more total bone
formationandlamellarboneformationthanmembrane-onlyandcontroldefects.Therewerenostatisticallysigniﬁcantdiﬀerences
in total bone formation between EMD/BC with or without membrane. Conclusion. EMD with BC might improve bone formation
in osseous defects more than membrane coverage alone; the use of a membrane had no signiﬁcant additive eﬀect on total bone
formation.
1.Introduction
Historically, augmentation or “regeneration” of alveolar
bone lost as a result of tooth extraction, periodontal disease,
and/or trauma has presented a signiﬁcant challenge. In this
context, many diﬀerent materials and techniques have been
developed and evaluated [1]. Enhancement of bone forma-
tion,improvementofthequalityofthenewbone,shortening
of the treatment period (especially for implant treatment),
simpliﬁed application of materials, and promotion of the
eﬀectiveness of biological processes are the primary goals of
regenerative treatment approaches [1, 2]. Incorporation of
biologic mediators into bone graft materials or other carriers
in bone augmentation process and regeneration of bone
defects around the tooth or/and implant may help improve
outcomes [1, 3].
Emdogain is a mixture of enamel matrix derivatives
(EMDs) that can be used as an osteopromotive agent for
the aforementioned bone augmentation/regeneration treat-
ments [1]. Emdogain has been shown to enhance the oste-
ogenic potential of bone marrow by increasing the total
number of stromal cells [4–6], enhancing the proliferation
of osteoblasts [7–12], promoting cell diﬀerentiation [7, 13–
16], and stimulating migration and viability of osteoblasts
[12], which can lead to improved bone regeneration. Thus,
in addition to using EMDs for treatment of periodontal2 The Scientiﬁc World Journal
lesions [17–19], the application of EMDs to improve bone
healing and increase the rate of bone formation has been
proposed [19–23]. However, because of its gelatinous nature,
Emdogain is not eﬀective in preserving the space for new
bone formation [23]; in addition, it has only “osteopro-
motive” properties, and its osteoinductive properties have
not yet been proven [24–27]. These observations have
spurred considerable research interest in the incorporation
ofEMDsintoavarietyofbonereplacementgraftstoenhance
wound stability and maintain space [26–34], but controversy
remainsregardingtheresultsofthesecombinationtherapies.
Bioactive ceramics such as hydroxyapatite (HA), trical-
cium phosphate (TCP), or a combination of them (into
biphasic calcium phosphate) are biocompatible materials
that provoke no or little inﬂammatory response and have
been accepted as bioactive osteoconductive scaﬀolds for new
bone formation and the ingrowth of osteoprogenitor cells
[35, 36]. Biphasic calcium phosphate biomaterials have been
developedtoachieveabetterresultinlivingtissuesthanpure
TCP or HA alone [30, 31, 37, 38]. Also, it has been shown
that the same amount of new bone is achieved but with
less residual graft material comparing with other bone graft
materials [39]. Biphasic calcium phosphate, a bone ceramic
(BC) with slow dissolution and substitution rates as well as
osteoconductive properties, couldpossibly actas a carrierfor
bone-stimulating proteins [36].
Therefore,theaimofthisstudyistoproposeanewmeth-
od for improving bone regeneration using a combination of
Emdogain and osteoconductive BC.
2. Method and Materials
Three male canines of a mixed Iranian breed and nearly
identical weights (25kg) were selected for the study. Animal
selection, management, and surgical protocols were accom-
plished in accordance with the guidelines of the animal and
human experimentation committee of Isfahan University of
Medical Sciences.
2.1. Surgical Procedure. General anesthesia was induced by
injecting acepromazine 1% (Neurotranq, Alfasan, Woerden,
The Netherlands; 0.02mL/kg) and ketamine hydrochloride
10% (Ketamine, Alfasan; 0.04mg/kg) and was completed
with inhalation anesthetic (Halothane BP, Nicholas Pira-
mal India Limited, India). The oral area was rinsed with
chlorhexidine 0.2% and then placed under local anesthesia
(Persocaine E, Lidocaine HCl 2% + epinephrine 1/80,000;
Daru Pakhsh Pharmaceutical Mfg Co, Tehran, Iran). All
mandibular premolars were then extracted.
Postoperative antibiotics, including penicillin and
streptomycin (Nasr Pharmaceutical Co, Fariman, Iran;
40,000IU/kg), were prescribed for 7 days, and tramadol
(Tehran Chemic Pharmaceutical Co, Tehran, Iran; 5mg/kg)
was applied for pain control. After 3 months of healing,
the animals were anesthetized as before; then, under local
anesthesia, full-thickness ﬂaps were created bilaterally
by making a crestal incision on the mandibular alveolar
processes 3mm from the canines to 2mm from the ﬁrst
molars. With a trephine bur (No. 6, Meisinger, Neuss,
Germany), four standardized cylindrical cavities with a
depth and diameter of 6mm were created on each side of
the mandible (3mm from each other) (Figure 1). Also, small
holes were drilled on the apical and lateral aspects of each
cavity with a round No. 2 bur that was ﬁlled with gutta-
percha. The bone defects on each side were randomly
assigned to one of the following four groups (Figure 1).
(i) EMD/BC with membrane: the defect was ﬁlled with
a combination of Emdogain (Institut Straumann,
Basel, Switzerland) and BC (OSTEON, Geonosis,
Suwan-si, Korea) and covered with a nonresorbable
membrane (Osteo-Mesh TM-300, CYTOPLAST,
Osteogenic Biomedical Inc, Lubbock, TX, USA) that
was ﬁxed with tacks (FRIOS, Dentsply/Friadent,
Mannheim, Germany).
(ii) EMD/BC without membrane: the defect was ﬁlled
with a combination of Emdogain and BC.
(iii) Membrane only: the defect was covered only with a
nonresorbable membrane that was held in place with
tacks.
(iv) Control: the defect was left untreated.
The ﬂaps were repositioned and closed with resorbable
polyglycolic acid sutures (PGA, TEB Keyhan, Eshtehard,
Iran). At the end of surgery, all animals received intramus-
cular injections of antibiotics and analgesics, as with the
ﬁrst surgery. During the ﬁrst 2 weeks after the surgery, the
dogs’ mouths were washed with chlorhexidine 0.2%, and the
animals were fed a soft diet rich in supplementary vitamins.
2.2. Retrieval of Specimens. T h ea n i m a l sw e r ec h e c k e dt w i c e
per day during the ﬁrst postoperative week for signs of
infection.Thethreeanimalswererandomlyassignedtothree
diﬀerent time intervals: 2 weeks, 4 weeks, and 6 weeks; at the
end of each designated healing period, each animal received
general anesthesia and was sacriﬁced by vital perfusion.
Each mandible was sectioned and ﬁxed in 10% neutral
buﬀered formalin. Eight harvested blocks containing the
specimens were obtained from each mandible (four speci-
mensfromeachside,onefromeachgroup).Theyweredecal-
ciﬁedin10%ethylenediaminetetraaceticacidfor8weeksand
then embedded in acrylic resin (Meliodent, Heraeus Kulzer,
Newbury, Berkshire, United Kingdom). With a microtome
(ACCU-Cut SRM200, Sakura Finetek Europe, Alphen aan
denRijn,TheNetherlands),buccolingualcross-sectionswere
obtained from the middle portion of the defects and were
ground to a ﬁnal thickness of 4μm. Two slides of each
specimen were stained with hematoxylin-eosin, and the
other two slides were prepared for immunohistochemical
analysis for markers of osteopontin (OPN) (Ncl-o-pontin,
mouse monoclonal, Leica Biosystems, Newcastle, United
Kingdom) by the polymer HRP method according to the
manufacturer.
2.3. Histologic and Histomorphometric Analyses. Slides were
examined by a blinded examiner under a light microscopeThe Scientiﬁc World Journal 3
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Figure 1: (a) Four cylindrical defects, 6mm deep and 6mm in diameter, were prepared on each side of the mandible. (b) The four types of
treated defects.
(Olympus CX21FS, Olympus Corporation, Tokyo, Japan) at
a magniﬁcation of ×100. For each section, the percentages
of total generated bone, woven bone, lamellar bone, and
existing ﬁbrous connective tissue were measured.
2.4. Immunohistochemical Analysis. The intensity of OPN
expression in bone matrix was examined on each slide by
light microscope. Based on the observation, OPN staining
intensity was ranked as no expression (−), mild expression
(+), moderate expression (++), or strong expression (+++).
3. Results
In this study, membrane exposures were observed in some
surgical sites during healing. In these cases, the membrane
was removed at 4 weeks, and the site was resutured in the
canine that healed for 6 weeks.
Histologic examination revealed that new bone had
formed in all experimental groups, especially in the apical
portions of the defects. Acute inﬂammation was observed
in only one specimen (from a site treated with EMD/BC
with membrane at 2 weeks) (Figure 2) .T h ep r e s e n c eo fb o t h
lamellar and woven bone in the specimens at all intervals (2,
4, and 6 weeks) suggested that bone remodeling was taking
place. Also, some residual materials were found in some
specimens in the EMD/BC-treated sites.
Table 1 and Figure 3 present the results of histomor-
phometric evaluation of the diﬀerent groups and intervals.
Repeated-measures analysis of variance showed that there
were statistically signiﬁcant diﬀerences in formation of total
bone, lamellar bone, and woven bone as well as the in the
existing ﬁbrous connective tissue between the groups (P<
.05). Based on the paired t-test, both EMD/BC with and
without membrane showed statistically signiﬁcant diﬀer-
ences in total bone formation and lamellar bone formation
compared with the membrane-only and the control groups
(P<. 05). However, there was a statistically signiﬁcant
diﬀerence in woven bone formation only with the control
group. EMD/BC with membrane had the most lamellar
bone formation, but this was not statistically signiﬁcantly
diﬀerent versus EMD/BC without membrane in the mean
percentages of total and woven bone formation (paired t-
test, P>. 05). Also, both EMD/BC experimental groups
(both with and without membrane) showed a statistically
signiﬁcant diﬀerence in existing ﬁbrous connective tissue
with the membrane-only and control groups, as well as with
each other (P<. 05).
The results of immunohistochemical evaluation and the
intensity of staining for OPN in the diﬀerent groups are
shown in Table 2; samples are shown in Figure 4.T h e
Friedman test demonstrated that there were statistically
signiﬁcant diﬀerences between all experimental groups, so
the Wilcoxon test was used to compare individual pairs
of groups, with the level of signiﬁcance set at α = .05.
It revealed that only EMD/BC with membrane showed a
statistically signiﬁcant diﬀerence versus the membrane-only
and control groups. There were no statistically signiﬁcant
diﬀerences between the other experimental groups regarding
the intensity of staining for OPN.
4. Discussion
In the present study, in the defects treated with EMD/BC
(with or without membrane), the mean percentage of new
bone formation was greater than that seen the control
and membrane-only groups during each interval. Also,
the quality of the newly formed bone was improved,
as evidenced by the higher percentage of lamellar bone
formed in the EMD/BC groups. This improvement in bone
formation might have resulted from the combined eﬀects
of EMD and BC. Emdogain is a commercially available
mixture of EMDs. The composition of EMDs has been
described as a hydrophobic enamel matrix protein complex
derived from 6-month-old porcine tooth buds containing
more than 90% amelogenin as well as enamelin, tuftelin,
tuft proteins, ameloblastin [40], and other peptides such
as bone morphogenetic proteins (BMPs) and transforming


























Figure 2: Histological views of new bone formation with hematoxylin-eosin staining (magniﬁcation ×100). (a) GBR group; (b) EMD/BC
without membrane; (c) EMD/BC with membrane; (d) control group. CT: connective tissue, LB: lamellar bone, WB: woven bone, OBR:
osteoblastic rim.
Table 1: Mean percentage (± SDs) of tissue areas for each experimental group.
Experimental group Tissue type
n Total bone formation Lamellar bone formation Woven bone formation Fibrous connective tissue
EMD/BC with membrane 6 47.5 ±7.55a 23.6 ±2.16a 23.8 ±5.81a 29.1 ±4.44a
EMD/BC without membrane 6 45.8 ±6.14a 21.6 ±3.77b 24.1 ±3.43a 32.8 ±2.48b
Membrane only 6 40.5 ±8.45b 15.5 ±8.45c 25.0 ±3.16a,b 39.5 ±5.04c
Control 6 34.5 ±8.33c 15.0 ±4.47c 19.5 ±5.04b 40.5 ±5.61c
a,b,cDiﬀerent superscript letters indicate statistically signiﬁcant diﬀerences (P<. 05). EMD/BC = Combination of Emdogain with BC (biphasic calcium
phosphate, i.e., TCP + HA).
that amelogenins are self-assembled into supermolecular
aggregates, which are generated in insoluble extracellular
matrix [43] with high aﬃnity for collagens and HA [44, 45].
In vitro studies have demonstrated that EMDs stimulate
bone cell proliferation and diﬀerentiation [5, 7, 8, 11, 12,
30, 46], aﬀecting bone formation. Takayama et al. reported
that BMP-like molecules (BMP-2, BMP-4, and BMP-7) in
EMDsencouragethepromotionofosteogenicdiﬀerentiation
[14]. Another study reported that the presence of EMDs can
inhibit myoblastic development of cultured pluripotential
mesenchymal cells and increase alkaline phosphatase activity
[13]. Goda et al. reported that the BMP-2 and TGF-β in
Emdogain can activate osteoblasts and enhance the produc-
tion of collagenase (i.e., matrix metalloproteinase-1), which
degrades matrix proteins in bone tissue microenvironments,
resulting in the facilitation of bone regeneration [47, 48].
On the other hand, the HA/TCP carrier acts as a
scaﬀold [36, 49]. This scaﬀold can play an important role
in facilitating the attachment of stimulated cells, as well
as promoting these cells to produce new bone [36]. It has
been shown that biphasic calcium phosphate can increase
the concentration of free calcium ions in the environment,
which acts as a calcium reservoir, thereby assisting with bone








































































































































Figure 3: The mean percentages of lamellar bone, woven bone,
and ﬁbrous connective tissue for each experimental group and
time interval. EMD/BC + M: EMD/BC with membrane; EMD/BC:
EMD/BC without membrane; M: membrane only; C: control.



























+++ 0 0 0 0
Ratings for OPN expression: −: no expression, +: mild expression, ++:
moderate expression, ++++: strong expression.
The increased bone formation shown in the present
study is in agreement with other in vivo investigations that
have demonstrated the role of enamel matrix proteins in
the regeneration of dehiscence type defects around implants
[21] and its osteopromotive eﬀect on bone regeneration
during the healing of injured bones [20]. Also, some studies
have shown that the use of Emdogain in combination with
bone graft materials can improve bone formation [29–34].
Potijanyakul et al. demonstrated that rat calvarial defects
ﬁlled with bioactive glass plus EMD showed a slightly higher
percentage of new bone formation than those ﬁlled with
bioactive glass alone [31]. In another study, the eﬀect of a
mixture of EMD and β-TCP on bone augmentation within a
titanium cap in rabbit calvaria was evaluated. It was shown
that the EMD promoted initial bone formation and matura-
tion of mineralized bone after 1 month. However, there was
nosigniﬁcantdiﬀerenceintheamountofnewlyformedbone
in EMD plus β-TCP compared with β-TCP alone in the 3-
month follow-up group. Hence, the authors suggested that
EMD did not promote osteoblastic activity but encouraged
osteogenic diﬀerentiation of pluripotent mesenchymal cells
[24]. Another study demonstrated that, although the appli-
cation of Emdogain with a membrane resulted in a slight
(but not signiﬁcant) increase in vertical bone formation,
the addition of Emdogain to bone graft materials did not
have any additional beneﬁts [23]. The results of previous
studies regarding the role of EMDs in bone formation have
proposed that Emdogain was more eﬀective when it was
combined with bone substitute materials for the treatment
of periodontal osseous defects [32, 51–53]. In contrast, other
studies have found that Emdogain in combination with bone
substitutedidnotsigniﬁcantlyenhancethepotentialfortotal
bone formation in osseous defects [27, 30, 54].
The diﬀerence in bone formation and osteogenic poten-
tial of EMD with or without bone grafting materials can be
explained either by the diﬀerent EMD concentrations that
were used or by the bone inductive properties of speciﬁc
bone substitute materials. Additionally, it is worth men-
tioning that if Emdogain does not increase bone formation
or osteoinduction, the possibility that EMDs are involved
in osteoblastic diﬀerentiation in general is not necessarily
excluded. Also, in vitro and in vivo studies have documented
that amelogenin proteins have osteogenic potential [23, 45,
55]. Thus, it could be concluded that the Emdogain used in
diﬀerent studies might not contain the appropriate amount
of amelogenins with osteogenic potential and has lower
concentrations of EMDs and amelogenin than is necessary
for achieving bone formation and osteoinduction.
Application of a membrane along with EMD/BC in the
presentstudyresultedinadecreaseintheexistenceofﬁbrous
connectivetissueandanincreaseinlamellarboneformation.
However, it did not have any signiﬁcant additional eﬀect on
total bone formation or woven bone formation, which is
consistent with some previous studies [23, 32].
In the present research, immunohistochemical evalua-
tion showed that the defects treated with a combination of
Emdogain and BC (with or without a membrane) had the
most intense staining, indicating more extracellular OPN
expression in these defects in comparison with the other
treatments. OPN is a noncollagenous phosphorylated acidic
glycoprotein that resides in the extracellular matrix of min-
eralized tissues and is produced by osteoblasts, osteoclasts,
osteocytes, preosteoblasts, some bone marrow cells, and
many nonbone cells [56, 57]. It has been shown that OPN
can bond to HA and calcium ions with its arginine-glycine-

























Figure 4: Immunohistochemical views of OPN stain intensity. ((a), magniﬁcation ×100) EMD/BC with membrane; ((b), ×400) EMD/BC
without membrane; ((c); ×400) GBR group; ((d), ×400) control group. LB: lamellar bone, WB: woven bone, OB: osteoblast, OC: osteoclast,
OPN: osteopontin-expressing cell.
bone remodeling, wound repair, angiogenesis, cell survival,
immune function, and several pathophysiological processes
[56, 58]. In mineralized tissue, OPN is secreted by both
osteoblasts and osteoclasts, and its concentration in areas of
newly formed bone should be increased [59]. Some previous
immunohistochemical studies have reported a progressive
increase, either in OPN detected in maturing membranous
bone matrix or in OPN expression by preosteoblasts and
osteoblasts in developing mandibular bone [59].
The increased expression of OPN in defects treated by
Emdogain/BC suggests that osteoblast diﬀerentiation and
osteoclastic activity were enhanced, indicating more bone
remodeling. Also, according to previous studies, EMDs may
accelerate expression of OPN [60], conﬁrming the useful
eﬀects of EMDs on periodontal and bone regeneration.
While the greatest amount of lamellar bone formation
was observed in the defects treated with EMD/BC and a
membrane, OPN staining was also intense in this group,
conﬁrmingitssuperiorboneremodeling.However,therewas
no signiﬁcant diﬀerence in OPN stain intensity between the
sites treated with EMD/BC with or without a membrane.
OPN is the important interﬁbrillar portion of type I collagen
in the extracellular matrix of woven bones [61]. Therefore, it
is suggested that the lack of signiﬁcant diﬀerence in woven
bone formation between these groups is paralleled by the
absence of signiﬁcant diﬀerences in OPN stain intensity.
It can be seen as a limitation of this study that BC alone,
without EMD, was not tested. However, the primary purpose
of the present study was to evaluate the role of a BC in bone
regeneration. Historically, bone graft materials have been
evaluated with and without a membrane. Future studies will
investigate the role of BC in regeneration procedures.
5. Conclusion
According to the results, Emdogain combined with bone
ceramic (TCP/HA) might improve bone formation in
osseous defects more than the use of membrane alone. It was
also observed that the use of a membrane in combination
with Emdogain and bone ceramic did not confer an ad-
vantage with regard to total bone formation.The Scientiﬁc World Journal 7
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